BIOMAT Database Logo BIOMAT Database Logo

Pharmacokinetics of sorafenib in patients with renal impairment undergoing hemodialysis. 2009

R A Hilger, and H Richly, and M Grubert, and S Kredtke, and D Thyssen, and W Eberhardt, and J Hense, and M Schuler, and M E Scheulen
Department of Internal Medicine, University of Essen Medical School, Essen, Germany. ralf.hilger@uni-duisburg-essen.de

UI MeSH Term Description Entries
D007674 Kidney Diseases Pathological processes of the KIDNEY or its component tissues. Disease, Kidney,Diseases, Kidney,Kidney Disease
D009536 Niacinamide An important compound functioning as a component of the coenzyme NAD. Its primary significance is in the prevention and/or cure of blacktongue and PELLAGRA. Most animals cannot manufacture this compound in amounts sufficient to prevent nutritional deficiency and it therefore must be supplemented through dietary intake. Nicotinamide,Vitamin B 3,Vitamin PP,3-Pyridinecarboxamide,Enduramide,Nicobion,Nicotinsäureamid Jenapharm,Papulex,Vitamin B3,3 Pyridinecarboxamide,B 3, Vitamin,B3, Vitamin,Jenapharm, Nicotinsäureamid
D010671 Phenylurea Compounds Compounds that include the amino-N-phenylamide structure. Phenylcarbamides,Phenylurea Derivatives,Compounds, Phenylurea,Derivatives, Phenylurea
D011725 Pyridines Compounds with a six membered aromatic ring containing NITROGEN. The saturated version is PIPERIDINES.
D001800 Blood Specimen Collection The taking of a blood sample to determine its character as a whole, to identify levels of its component cells, chemicals, gases, or other constituents, to perform pathological examination, etc. Blood Specimen Collections,Collection, Blood Specimen,Collections, Blood Specimen,Specimen Collection, Blood,Specimen Collections, Blood
D002986 Clinical Trials as Topic Works about pre-planned studies of the safety, efficacy, or optimum dosage schedule (if appropriate) of one or more diagnostic, therapeutic, or prophylactic drugs, devices, or techniques selected according to predetermined criteria of eligibility and observed for predefined evidence of favorable and unfavorable effects. This concept includes clinical trials conducted both in the U.S. and in other countries. Clinical Trial as Topic
D004305 Dose-Response Relationship, Drug The relationship between the dose of an administered drug and the response of the organism to the drug. Dose Response Relationship, Drug,Dose-Response Relationships, Drug,Drug Dose-Response Relationship,Drug Dose-Response Relationships,Relationship, Drug Dose-Response,Relationships, Drug Dose-Response
D004334 Drug Administration Schedule Time schedule for administration of a drug in order to achieve optimum effectiveness and convenience. Administration Schedule, Drug,Administration Schedules, Drug,Drug Administration Schedules,Schedule, Drug Administration,Schedules, Drug Administration
D006435 Renal Dialysis Therapy for the insufficient cleansing of the BLOOD by the kidneys based on dialysis and including hemodialysis, PERITONEAL DIALYSIS, and HEMODIAFILTRATION. Dialysis, Extracorporeal,Dialysis, Renal,Extracorporeal Dialysis,Hemodialysis,Dialyses, Extracorporeal,Dialyses, Renal,Extracorporeal Dialyses,Hemodialyses,Renal Dialyses
D006801 Humans Members of the species Homo sapiens. Homo sapiens,Man (Taxonomy),Human,Man, Modern,Modern Man

Related Publications

R A Hilger, and H Richly, and M Grubert, and S Kredtke, and D Thyssen, and W Eberhardt, and J Hense, and M Schuler, and M E Scheulen
Pharmacokinetics of topiramate in patients with renal impairment, end-stage renal disease undergoing hemodialysis, or hepatic impairment.
July 2014, Epilepsy research,
R A Hilger, and H Richly, and M Grubert, and S Kredtke, and D Thyssen, and W Eberhardt, and J Hense, and M Schuler, and M E Scheulen
Use of sorafenib in two metastatic renal cell cancer patients with end-stage renal impairment undergoing replacement hemodialysis.
January 2009, Tumori,
R A Hilger, and H Richly, and M Grubert, and S Kredtke, and D Thyssen, and W Eberhardt, and J Hense, and M Schuler, and M E Scheulen
Pharmacokinetics of tobramycin in patients with stable renal impairment, patients undergoing peritoneal dialysis, and patients on chronic hemodialysis.
June 1974, Antimicrobial agents and chemotherapy,
R A Hilger, and H Richly, and M Grubert, and S Kredtke, and D Thyssen, and W Eberhardt, and J Hense, and M Schuler, and M E Scheulen
[Pharmacokinetics of propranolol in patients with chronic renal insufficiency undergoing hemodialysis].
January 1979, Therapie,
R A Hilger, and H Richly, and M Grubert, and S Kredtke, and D Thyssen, and W Eberhardt, and J Hense, and M Schuler, and M E Scheulen
Pharmacokinetics of cefaclor in patients with stable renal impairment, and patients undergoing haemodialysis.
July 1979, The Journal of antimicrobial chemotherapy,
R A Hilger, and H Richly, and M Grubert, and S Kredtke, and D Thyssen, and W Eberhardt, and J Hense, and M Schuler, and M E Scheulen
Pharmacokinetics of piperacillin in patients with moderate renal failure and in patients undergoing hemodialysis.
February 1981, Antimicrobial agents and chemotherapy,
R A Hilger, and H Richly, and M Grubert, and S Kredtke, and D Thyssen, and W Eberhardt, and J Hense, and M Schuler, and M E Scheulen
Pharmacokinetics of ceftriaxone in patients with renal failure and in those undergoing hemodialysis.
October 1983, Antimicrobial agents and chemotherapy,
R A Hilger, and H Richly, and M Grubert, and S Kredtke, and D Thyssen, and W Eberhardt, and J Hense, and M Schuler, and M E Scheulen
Pharmacokinetics of ceftazidime in patients with renal insufficiency and in those undergoing hemodialysis.
January 1985, Chemotherapy,
R A Hilger, and H Richly, and M Grubert, and S Kredtke, and D Thyssen, and W Eberhardt, and J Hense, and M Schuler, and M E Scheulen
Pharmacokinetics of cefmenoxime in patients with impaired renal function and in those undergoing hemodialysis.
December 1986, Antimicrobial agents and chemotherapy,
R A Hilger, and H Richly, and M Grubert, and S Kredtke, and D Thyssen, and W Eberhardt, and J Hense, and M Schuler, and M E Scheulen
Pharmacokinetics of cefotiam in patients with impaired renal function and in those undergoing hemodialysis.
November 1984, Antimicrobial agents and chemotherapy,
Copied contents to your clipboard!